CCCC - C4 Therapeutics Short-Term Debt to Capital
The tracked asset value for C4 Therapeutics, Inc. (CCCC) on the chart is 0.04. C4 Therapeutics, Inc. (CCCC) faces clinical trial uncertainty and costly development, risking a loss of ground to more modern treatments. Management is betting on its proprietary protein degradation platform. The business relies on an autonomous innovation cycle, making it resilient to macroeconomic fluctuations and a reliable defensive asset.
Summary analytical data breakdowns for c4therapeutics.com (CCCC)
This ratio determines the extent of the company's dependence on liabilities with a maturity of over one year relative to its own equity. The dynamics of the short-term debt-to-equity ratio allow for the timely identification of excessive credit load risks. The metric is calculated by dividing the total amount of long-term loans by the equity value, reflecting the financial stability of the structure. For C4 Therapeutics, Inc. (CCCC), this balance is critical for maintaining laboratories in Massachusetts and paying external partners for molecule synthesis.